secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001213900-24-093768
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar to sell Huntsville PEGylation plant to Ampersand for $90M
----------------------------------------------------------------

- Total consideration $90M ($70M cash, $20M equity in new Ampersand portfolio co.).
- Expected close by Dec 2, 2024; all Huntsville employees offered jobs at new co.
- Nektar retains existing royalty/milestone rights; enters supply agreements for PEG reagents.
- Sale not subject to financing; extends Nektar cash runway into Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390024093768/0001213900-24-093768-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390024093768/ea0219747-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-093768

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer